Highest-materiality recent filing
Nordicus Partners establishes board committees, appoints members and chairs
Audit Committee: Kim Mücke (Chair, financial expert), Andrew J. Ritter, Peter Severin.
Nordicus Partners raises ~$360k via issuance of 131k restricted shares at $2.75/share
Issued 131,000 restricted shares to ten private investors at $2.75 per share.
Nordicus Partners closes private placement of 416,000 shares at $2.75 each
Issued 416,000 restricted common shares to eight private investors at $2.75/share.
Nordicus Partners closes private placement of 1,057,500 shares at $1.90 to 54 investors
Issued 1,057,500 restricted common shares at $1.90 per share from July to September 2025; closed Sept 18, 2025.
Nordicus Partners furnishes independent valuations for Orocidin and Bio-Convert subsidiaries
Stanton Park Advisors LLC prepared valuation reports for Orocidin's QR-01 and Bio-Convert's QR-02 as of June 30, 2025.
Nordicus appoints three new directors after Keller resignation
Henrik Keller resigned from Board effective August 7, 2025 to pursue other interests.
Nordicus Partners issues 35,000 restricted shares at $4.00 in private placement
Sold 35,000 restricted common shares on June 16, 2025 at $4.00/share, raising $140,000.
Nordicus Partners approves one-year CEO and CFO pay packages of $360K and $120K
CEO Henrik Rouf's amended employment agreement provides base salary of $360,000/year for one year starting July 1, 2025.
Nordicus Partners issues 54,000 restricted shares at $5.00 each in private placement
Issued 54,000 restricted shares of common stock at $5.00/share to two private investors in April and May 2025.
Nordicus Partners to present on Bio-Convert A/S; no new financial data in filing
Presentation to analysts and investors regarding wholly owned subsidiary Bio-Convert A/S on or after April 1, 2025.
Nordicus Partners furnishes investor presentation on Orocidin A/S subsidiary
Company filed Regulation FD disclosure to provide a presentation about its wholly owned subsidiary Orocidin A/S.
Nordicus Partners grants warrant to buy 1M shares at $8.91 floor to Danish investor
Issued warrant to purchase 1,000,000 shares of common stock to GK Partners ApS on December 30, 2024.
Nordicus Partners files 8-K to furnish investor presentation; no details provided
Company furnishes a presentation to analysts and investors on or after January 2, 2025.
Consulting agreement with Harbor Access LLC for $8,000/month, term through November 30, 2025.
Nordicus Partners acquires 100% of Bio-Convert ApS for 12M restricted shares
Acquired 100% of Danish clinical-stage biopharma Bio-Convert ApS on Nov 12, 2024.
Nordicus acquires remaining ~5% of Orocidin, making it wholly owned subsidiary
Acquired 29,663 Orocidin shares (5.34% of outstanding) for 200,000 restricted common shares.
Nordicus appoints Peter Severin as chairman after Christian Hill-Madsen resigns
Christian Hill-Madsen resigned from the board effective June 3, 2024; will remain Chairman of Orocidin A/S (95% owned by Nordicus).
Nordicus acquires 95% of Orocidin A/S for $38M in stock, enters periodontitis market
Acquired 525,597 Orocidin shares (95% stake) from 11 shareholders for 38M restricted common shares.
and the remaining Board members appointed Peter Severin as his replacement and as Chairman of the Board of Directors.
Effective June 3, 2024, Christian Hill-Madsen resigned from the Board of Directors of Nordicus Partners Corporation (the “Company”), and the remaining Board members appointed Peter Severin as his replacement and as Chairman of the Board of Directors.
Max materiality 0.90 · Median 0.38 · Most common event other_material